Aromatase inhibitors and musculoskeletal adverse events : The Lancet Oncology
".........Because symptom collection is so variable between trials, researchers
could look for correlations between changes in patient-reported quality
of life and breast-cancer outcomes. Nevertheless, if clinical research
confirms a link between emergent symptoms or changes in quality of life
and breast-cancer outcomes, further pharmacogenomic and pharmacogenetic
studies could help to elucidate the mechanisms. Although confirmation of
the association between emergent symptoms with aromatase inhibitors and
risk of breast-cancer recurrence would help to guide clinical advice,
based on current evidence clinicians should not use the onset of
musculoskeletal symptoms to infer which patient will, or will not,
benefit from adjuvant treatment with aromatase inhibitors."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.